Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use

被引:108
|
作者
Palepu, A
Tyndall, M
Yip, B
O'Shaughnessy, MV
Hogg, RS
Montaner, JSG
机构
[1] Univ British Columbia, St Pauls Hosp, Ctr Hlth Evaluat & Outcome Sci, Vancouver, BC V5Z 1M9, Canada
[2] Univ British Columbia, St Pauls Hosp, Dept Med, Vancouver, BC V5Z 1M9, Canada
[3] Univ British Columbia, St Pauls Hosp, British Columbia Ctr Execllence HIV AIDS, Vancouver, BC V5Z 1M9, Canada
[4] Univ British Columbia, Dept Hlth Care & Epidemiol, Vancouver, BC V5Z 1M9, Canada
[5] Univ British Columbia, Dept Pathol, Vancouver, BC V5Z 1M9, Canada
关键词
anti-HIV agents; HIV infections; human; logistic regression models; substance abuse; intravenous;
D O I
10.1097/00126334-200304150-00009
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Injection drug users who continue to use drugs may not respond to highly active antiretroviral therapy (HAART) as well as other HIV-infected individuals, even after adjusting for a reliable measure of adherence. We therefore compared the virologic response. among participants in a population-based HIV/AIDS Drug Treatment Program in British Columbia, Canada, by injection drug use activity. Participants who were HIV infected and naive to antiretroviral therapy and who were prescribed antiretroviral treatment between August 1996 and December 2000 were eligible for this study. They were classified as current, former, or non-injection drug users. The main outcome was having two consecutive HIV-1 RNA levels less than 500 copies/mL. We used logistic regression to adjust for baseline HIV-1 RNA, type of antiretroviral regimen (2 nucleosides + nonnucleoside reverse transcriptase inhibitor versus 2 nucleosides + protease inhibitor), duration of therapy (months), adherence (derived from refill compliance data), and age. A total of 578 participants were first prescribed HAART during the study period. Among them, 78 (13%) were current injection drug users, 96 (17%) were former injection drug users, and 404 (70%) never injected drugs. In the multivariable logistic regression, relative to non-drug users, current injection drug users were significantly less likely to suppress their HIV-1 RNA (adjusted OR [AOR] = 0.30, 95% CI: 0.13-0.67), and former injection drug users were not significantly different from non-drug users (AOR = 0.56, 95% CI: 0.24-1.34). There was a significant interaction between drug use and adherence. In the analyses stratified by drug use, the adherence of former and non-drug users was positively associated with HIV-1 RNA suppression (AOR = 1.33, 95% CI: 1.14-1.55), whereas for current drug users, it was not (AOR = 1.07, 95% CI: 0.87-1.33). Current injection drug users were less likely to achieve HIV-1 RNA suppression compared with non-drug users. Adherence as measured by pharmacy refill compliance was not a reliable measure in this subpopulation.
引用
收藏
页码:522 / 526
页数:5
相关论文
共 50 条
  • [1] Virologic and immunologic response to highly active antiretroviral therapy
    Lisa P. Jacobson
    John P. Phair
    Traci E. Yamashita
    Current Infectious Disease Reports, 2002, 4 (1) : 88 - 96
  • [2] Ongoing drug use and outcomes from highly active antiretroviral therapy among injection drug users in a Canadian setting
    Krusi, Andrea
    Milloy, M-J
    Kerr, Thomas
    Zhang, Ruth
    Guillemi, Silvia
    Hogg, Robert
    Montaner, Julio
    Wood, Evan
    ANTIVIRAL THERAPY, 2010, 15 (05) : 789 - 796
  • [3] Update on the virologic and immunologic response to highly active antiretroviral therapy
    Jacobson L.P.
    Phair J.P.
    Yamashita T.E.
    Current Infectious Disease Reports, 2004, 6 (4) : 325 - 332
  • [4] Virologic and immunologic response to highly active antiretroviral therapy.
    Jacobson L.P.
    Phair J.P.
    Yamashita T.E.
    Current HIV/AIDS Reports, 2004, 1 (2) : 74 - 81
  • [5] Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence
    Press, N
    Tyndall, MW
    Wood, E
    Hogg, RS
    Montaner, JSG
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2002, 31 : S112 - S117
  • [6] Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy
    Pence, Brian Wells
    Miller, William C.
    Gaynes, Bradley N.
    Eron, Joseph J., Jr.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2007, 44 (02) : 159 - 166
  • [7] Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study
    Yamashita, TE
    Phair, JP
    Muñoz, A
    Margolick, JB
    Detels, R
    O'Brien, SJ
    Mellors, JW
    Wolinsky, SM
    Jacobson, LP
    AIDS, 2001, 15 (06) : 735 - 746
  • [8] Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy.
    Pence, B. W.
    Miller, W. C.
    Gaynes, B. N.
    Eron, J. J., Jr.
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2007, 165 (11) : S104 - S104
  • [9] Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited
    Moore, AL
    Kirk, O
    Johnson, AM
    Katlama, C
    Blaxhult, A
    Dietrich, M
    Colebunders, R
    Chiesi, A
    Lungren, JD
    Phillips, AN
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 32 (04) : 452 - 461
  • [10] Relationship between levels of indinavir in hair and virologic response to highly active antiretroviral therapy
    Bernard, L
    Vuagnat, A
    Peytavin, G
    Hallouin, MC
    Bouhour, D
    Nguyen, TH
    Vildé, JL
    Bricaire, F
    Raguin, G
    de Truchis, P
    Ghez, D
    Duong, M
    Perronne, C
    ANNALS OF INTERNAL MEDICINE, 2002, 137 (08) : 656 - 659